For two decades after the 2002 Women’s Health Initiative, hormone replacement therapy was widely avoided based largely on early results from a single large trial that have since been re-analyzed and placed in context. Modern guidance from major societies — including The Menopause Society (formerly the North American Menopause Society) and the American College of Obstetricians and Gynecologists (ACOG) — describes hormone therapy as the most effective treatment for moderate-to-severe vasomotor symptoms, with a benefit-risk profile that is generally favorable for healthy women under 60 or within 10 years of menopause. Understanding what the current evidence actually says — and where genuine uncertainty remains — helps women and clinicians make individualized decisions. This article is educational and not a substitute for a conversation with your own prescriber.
A Note on Terminology
The older phrase “hormone replacement therapy” is still widely searched, but clinical societies now prefer hormone therapy (HT) or menopausal hormone therapy (MHT). The word “replacement” implied the goal was to restore youthful hormone levels, whereas the modern aim is to relieve symptoms at the lowest effective dose. You will see all of these terms used interchangeably; they refer to the same category of treatment.
What Hormone Therapy Is
Hormone therapy replaces estrogen and — when the uterus is present — a progestogen, to alleviate symptoms of estrogen deficiency around and after menopause. It is used primarily for vasomotor symptoms (hot flashes and night sweats), genitourinary syndrome of menopause (GSM), and prevention of osteoporosis in women at significant fracture risk who cannot tolerate or have failed other agents.
According to The Menopause Society (then NAMS) 2022 Hormone Therapy Position Statement, “for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture.” Importantly, hormone therapy is not recommended solely to prevent chronic conditions such as coronary heart disease or dementia. For broader context, see our guide to women’s health conditions.
Who Is a Candidate (and Who Is Not)
Good candidates include women with bothersome hot flashes or night sweats, those experiencing sleep disruption from menopause symptoms, women with genitourinary syndrome of menopause unresponsive to vaginal estrogen alone, and those with primary ovarian insufficiency or surgical menopause before the natural age — for whom hormone therapy is generally recommended at least until around the average age of natural menopause (about 51) to mitigate cardiovascular and bone risks, unless there is a contraindication.
Consistent with ACOG clinical guidance and The Menopause Society, generally accepted contraindications to systemic estrogen include unexplained vaginal bleeding, known or suspected estrogen-sensitive cancer (especially breast cancer), active or recent venous thromboembolism, active liver disease, recent stroke or heart attack, and pregnancy. Cautions include high triglycerides, gallbladder disease, migraine with aura, and active smoking after age 35. Because individual histories vary, only your clinician can determine whether hormone therapy is appropriate for you.
Types of Hormones and Routes of Delivery
Estrogen options include 17-beta estradiol (the same molecule the ovaries produce, available as oral tablets, transdermal patches, gels, sprays, and vaginal preparations), conjugated equine estrogens, and esterified estrogens. Transdermal (through-the-skin) estradiol bypasses first-pass liver metabolism and, in observational and meta-analytic data summarized in journals such as the BMJ, appears to carry lower thrombotic risk than oral estrogen. This makes it a common preference for women with elevated baseline clot risk, migraine, or high triglycerides — though the choice is individualized.
Progestogens are required for women with an intact uterus to prevent endometrial hyperplasia and cancer. Micronized progesterone (Prometrium) is the bioidentical option and may have a more favorable breast and metabolic profile than some synthetic progestins, according to evidence summarized by The Menopause Society. Other options include medroxyprogesterone acetate, norethindrone acetate, and the levonorgestrel-releasing IUD, which provides effective endometrial protection.
“Bioidentical” hormones — meaning estradiol and micronized progesterone — are FDA-approved and widely available through standard pharmacies. Compounded “bioidentical hormone therapy” prepared by compounding pharmacies is not FDA-regulated for purity, dose accuracy, or clinical outcomes, and The Menopause Society specifically advises against routine use of compounded hormone therapy when FDA-approved options exist.
Benefits Backed by Evidence
Hormone therapy reduces hot flash frequency and severity substantially — by roughly 75 percent in randomized trials. It improves sleep quality in women whose sleep is fragmented by night sweats. It treats vaginal atrophy and painful intercourse, though local low-dose vaginal therapy is preferred when genitourinary symptoms are the primary concern. It preserves bone density and reduced vertebral and hip fractures by roughly 30 to 40 percent in the WHI estrogen arm.
For women starting hormone therapy under age 60 or within 10 years of menopause, observational data and re-analysis of WHI data suggest possible cardiovascular benefit — the so-called “timing hypothesis” — though this is not, on its own, an approved indication for starting therapy. Quality of life, mood symptoms, and joint aches often improve as well, per data summarized in the journal Menopause. These are averages; individual responses vary.
Risks and How to Think About Them
Risks vary by formulation, route, dose, timing, and a woman’s baseline health. The 2022 position statement quantifies key risks. Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk after about five years of use — on the order of less than 1 additional case per 1,000 women per year of use. Estrogen-alone therapy showed no increased breast cancer risk, and possibly a slight decrease, in the WHI follow-up.
Oral estrogen is associated with a roughly two-fold increase in venous thromboembolism risk, while transdermal estradiol does not appear to elevate clot risk meaningfully in observational data. Stroke risk is slightly elevated with oral estrogen but not clearly with transdermal in observational studies. Endometrial cancer risk is increased with unopposed estrogen in women with a uterus, which is exactly why a progestogen is essential for them.
Common side effects in the first few months include breast tenderness, breakthrough bleeding, headache, bloating, and mood changes. Most diminish with time or a dose adjustment guided by your prescriber.
The 2025 FDA Label Change
A significant regulatory shift occurred in late 2025. On November 10, 2025, the FDA announced it would remove the long-standing boxed (“black box”) warning from estrogen-containing hormone therapy products, including systemic and low-dose vaginal estrogen, and rewrite labeling with age-specific guidance. The agency and its advisers argued that the original warning — rooted in the older WHI population, which was on average older and higher-risk than typical users — overstated risks for many women who start therapy near menopause. As Harvard Health reports, a boxed warning about endometrial cancer is expected to remain on systemic estrogen-alone products.
Because these labeling changes were announced to roll out over roughly six months, the exact wording on any given product may still be changing. This is a reason to review the current, FDA-approved labeling and your personal risk profile directly with your prescriber rather than relying on older package inserts or headlines.
Non-Hormonal Alternatives
For women who cannot or prefer not to take hormones, effective non-hormonal options have expanded. Fezolinetant (Veozah), a neurokinin-3 receptor antagonist, was FDA-approved in 2023 for moderate-to-severe hot flashes; it later received a boxed warning (2024) for rare liver injury, so it requires baseline and periodic liver blood-test monitoring. Elinzanetant (Lynkuet), a dual neurokinin-1/neurokinin-3 receptor antagonist, was FDA-approved in October 2025 as another hormone-free option for vasomotor symptoms. Older non-hormonal choices include certain SSRIs/SNRIs, gabapentin, and paroxetine (Brisdelle). Each has its own risks and monitoring, and the right choice is individualized.
When to See a Doctor
Anyone considering hormone therapy should have an individualized risk-benefit conversation with a qualified clinician; a Menopause Society Certified Practitioner is well-positioned for this discussion. Reassessment (often annually) is recommended, focusing on whether symptoms still warrant treatment and whether the woman’s risk profile has changed.
While on therapy, see a clinician promptly for a new breast lump, unscheduled or persistent vaginal bleeding, persistent pelvic pain, or signs of liver problems. Routine breast cancer screening with mammography should continue per age-appropriate guidelines.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden chest pain or shortness of breath, calf pain or swelling, severe headache, one-sided weakness or facial droop, sudden vision change, or coughing up blood — these may indicate a clot, stroke, or pulmonary embolism.
Frequently Asked Questions
Does HRT cause weight gain?
Hormone therapy does not cause significant weight gain on average. The WHI showed no statistically significant weight difference between hormone and placebo groups. Bloating and breast fullness are common in the first few weeks but usually resolve.
How long can you stay on hormone therapy?
The Menopause Society no longer recommends a strict, arbitrary duration limit. The decision to continue is individualized, based on symptoms, benefits, risks, and preferences, with periodic reassessment. Some women safely continue therapy beyond age 65 when the benefits still outweigh the risks, a judgment that should be made with a clinician.
Are bioidentical hormones safer than synthetic ones?
FDA-approved estradiol and micronized progesterone are bioidentical, and some evidence suggests micronized progesterone has a more favorable breast profile than medroxyprogesterone acetate. Compounded bioidentical hormones, however, are not FDA-regulated and have no demonstrated safety advantage — The Menopause Society advises against their routine use.
Can I start HRT years after menopause?
The benefit-risk balance becomes less favorable when systemic therapy is initiated more than 10 years past menopause or after age 60, particularly for cardiovascular outcomes. Low-dose vaginal estrogen for genitourinary symptoms can still be appropriate at essentially any age. Starting systemic therapy in late postmenopause warrants a careful, individualized discussion with your clinician.
Did the FDA say hormone therapy is now risk-free?
No. Removing the boxed warning reflects a judgment that the previous warning overstated risk for many women near menopause; it does not mean hormone therapy is free of risk or right for everyone. Contraindications and individual risk factors still apply, and the choice remains prescriber-directed.
The Bottom Line
For most healthy women in their 40s and 50s with bothersome menopause symptoms, hormone therapy is a reasonable, evidence-based option that was arguably over-avoided for two decades. The choice between transdermal versus oral estrogen, micronized progesterone versus other progestogens, and dose level should be individualized. Non-hormonal options such as fezolinetant and elinzanetant give more women effective alternatives. With the 2025 FDA labeling change still rolling out, a clinician who is up to date on current menopause guidance can help you weigh your specific symptom burden, risk factors, and preferences.
This article is general educational information, not medical advice. Hormone therapy is a prescription treatment; whether it is appropriate for you, and which type, dose, and route to use, is an individualized decision made with your prescriber. Regulatory labeling (including the 2025 removal of the boxed warning) continues to evolve, so review current, FDA-approved product labeling with your clinician. Call 911 for symptoms of a possible clot, stroke, or heart attack.
Sources
- The Menopause Society — 2022 Hormone Therapy Position Statement (menopause.org)
- FDA — November 10, 2025 announcement on removing boxed warnings from estrogen-containing hormone therapy products
- Harvard Health — “FDA removes menopause hormone therapy black box warnings” (2025)
- ACOG — Clinical guidance on menopausal symptom management (acog.org/clinical)
- FDA — Veozah (fezolinetant) labeling and 2024 hepatotoxicity boxed warning; Lynkuet (elinzanetant) October 2025 approval
- BMJ — Transdermal versus oral estrogen and venous thromboembolism risk